Drug intelligence / Profile preview

J2H-2201

Development stage: Preclinical
Lead developer: J2H Biotech
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

J2H-2201 is an investigational drug candidate being developed by J2HBiotech for the treatment of non-small cell lung cancer. It is classified as a targeted protein degradation (TPD) therapy, a modality that leverages the cell’s own protein disposal machinery to selectively degrade disease-causing proteins. The specific molecular target and mechanism of action for J2H-2201 have not been publicly disclosed, but it is part of a pipeline focused on novel approaches to cancer therapy using TPD technology. As of June 2025, J2H-2201 remains in preclinical or early clinical development stages[5].

Beyond the preview

Go deeper on J2H-2201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J2H-2201.

Explore the full profile